1921
Volume 88, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Immunization remains the most cost effective method for the control of infectious diseases. Therefore, there is a global effort to deploy new vaccines for disease control and eradication. These new vaccines must be tested in the settings in which they will be used. This necessity has required the conduct of many vaccine trials in Africa, where several infectious diseases with significant public health impact are prevalent. However, these areas have peculiarities and are just beginning to gain expertise in the conduct of such trials. The vaccine developers and sponsors of these trials may also not be conversant with some issues unique to the trial site. The understanding gap from both partners can result in challenges if not addressed during the planning phase of the trial. This review seeks to highlight the issues surrounding the conduct of clinical trials in resource-constrained settings and suggests some ways of circumventing them.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.12-0576
2013-03-06
2018-12-17
Loading full text...

Full text loading...

/deliver/fulltext/14761645/88/3/414.html?itemId=/content/journals/10.4269/ajtmh.12-0576&mimeType=html&fmt=ahah

References

  1. Duclos P, Okwo-Bele JM, Gacic-Dabo M, Cherian T, , 2009. Global immunization: status, progress, challenges and future. BMC Int Health Hum Rights 9 (Suppl 1): S2. [Google Scholar]
  2. Birn AE, , 2011. Small(pox) success? Cien Saude Colet 16: 591597.[Crossref] [Google Scholar]
  3. Craddock S, , 2012. Drug partnerships and global practices. Health Place 18: 481489.[Crossref] [Google Scholar]
  4. Rehnquist J, , 2001.The Globalization of Clinical Trials, a Growing Challenge in Protecting Human Subjects. Available at: http://oig.hhs.gov/oei. Accessed June 25, 2012. [Google Scholar]
  5. Beurret M, Hamidi A, Kreeftenberg H, , 2012. Development and technology transfer of Haemophilus influenzae type b conjugate vaccines for developing countries. Vaccine 30: 48974906.[Crossref] [Google Scholar]
  6. Louisa M, Takeuchi M, Steiabudy R, Nafrialdi Takeuchi M, , 2012. Current status of phase I clinical trials in Asia: an academic perspectives. Acta Med Indones 44: 7177. [Google Scholar]
  7. Cutts FT, Zaman SMA, Enwere G, Jaffar S, Levine OS, Okoko BJ, Oluwalana C, Vaughan A, Obaro SK, Leach A, McAdam KP, Biney E, Saaka M, Onwuchekwa U, Yallop F, Pierce NF, Greenwood BM, Adegbola RA, , 2005. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365: 11391146.[Crossref] [Google Scholar]
  8. Kremer M, Jaffe AB, Lerner J, Stern S, , 2001. Creating markets for new vaccines, Part I: Rationale. , eds. Innovation Policy and the Economy. Volume 1. Cambridge, MA: MIT Press, 3572. [Google Scholar]
  9. Shapiro HT, Meslin EM, , 2001. Ethical issues in the design and conduct of clinical trials in developing countries. N Engl J Med 345: 138141. [Google Scholar]
  10. 1998. Ethical issues facing medical research in developing countries. Gambia Government/Medical Research Council Joint Ethical Committee. Lancet 351: 286287.[Crossref] [Google Scholar]
  11. UNICEF/WHO, 2011. Immunization Summary. Available at: http://www.unesco.org/new/fileadmin/MULTIMEDIA/HQ/ED/GMR. Accessed August 3, 2012. [Google Scholar]
  12. Arenas-Lopez S, Fajardo C, Valls SA, Gracias-Corzo JR, Lima-Rogel MV, Calle G, Leite R, Lobos E, Hume-Wright Q, MacLeod S, , 2011. Pediatric clinical trials in Latin America and Guyana: present views of local practitioners and ways to embrace the future. Paediatr Drugs 13: 257265.[Crossref] [Google Scholar]
  13. Steketee RW, Campbell CC, , 2010. Impact of national malaria control scale-up programmes in Africa: magnitude and attribution of effects. Malar J 9: 299.[Crossref] [Google Scholar]
  14. Preziosi MP, Yam A, Ndiaye M, Simagu A, Simondon F, , 1997. Practical experiences in obtaining informed consent for a vaccine trial in rural Africa. N Engl J Med 336: 370373.[Crossref] [Google Scholar]
  15. Cressey D, , 2012. Informed consent on trial. Nature 482: 16.[Crossref] [Google Scholar]
  16. Lang T, , 2011. Adaptive trial design: could we use this approach to improve clinical trials in the field of global health? Am J Trop Med Hyg 85: 967970.[Crossref] [Google Scholar]
  17. Fairhead J, Leach M, Small M, , 2006. Public engagement with science? Local understandings of a vaccine trial in the Gambia. J Biosoc Sci 38: 103116.[Crossref] [Google Scholar]
  18. UNESCO, 2010. Education for All Global Monitoring Report. Reaching the Marginalized. Available at: http://www.unesco.org/new/fileadmin/MULTIMEDIA/HQ/ED/GMR. Accessed October 17, 2012. [Google Scholar]
  19. Erulkar AS, Muthengi E, , 2009. Evaluation of Berhane Hewan: a program to delay child marriage in rural Ethiopia. Int Perspect Sex Reprod Health 35: 614.[Crossref] [Google Scholar]
  20. Ota MO, Idoko OT, Ogundare EO, Afolabi MO, , 2012. Human immune responses to vaccines in the first year of life: biological, socio-economic and ethical issues: a viewpoint. Vaccine 2012 Jun 19 [Epub ahead of print]. [Google Scholar]
  21. Nunez-Wallace KR, Gill CE, Harrison CH, Taylor HM, Charles PD, , 2010. Discordance in informed consent response on the basis of demographic factors: brief report. Intellect Dev Disabil 48: 175179.[Crossref] [Google Scholar]
  22. Sow SO, Okoko BJ, Diallo A, Viviani S, Carlone G, Tapia M, Borrow R, Akinsola AK, Arduin P, Findlow H, Elie C, Haidara FC, Parulekar V, Chaumont J, Martellet L, Diallo F, Idoko OT, Tang Y, Plikaytis BD, Kulkarni PS, Marchetti E, Laforce FM, Preziosi MP, , 2011. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 364: 22932304.[Crossref] [Google Scholar]
  23. Howie SR, , 2011. Blood sample volumes in child health research: review of safe limits. Bull World Health Organ 89: 4653.[Crossref] [Google Scholar]
  24. Kaufmann JR, Feldbaum H, , 2009. Diplomacy and the polio immunization boycott in northern Nigeria. Health Aff (Millwood) 28: 10911101.[Crossref] [Google Scholar]
  25. Englev E, Petersen KP, , 2003. ICH-GCP Guideline: quality assurance of clinical trials. Status and perspectives [in Danish]. Ugeskr Laeger 165: 16591662. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.12-0576
Loading
  • Received : 16 Sep 2012
  • Accepted : 22 Nov 2012

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error